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Simple Summary: Discordant FDG-positive but PSMA-negative (FDG+/PSMA−) metastases con-
stitute a negative prognostic marker of overall survival in patients undergoing PSMA radioligand
therapy (RLT). The aim of this analysis was to investigate the prognostic implications of new
FDG+/PSMA− lesions, which occur during or after PSMA RLT. In a retrospective bicentric analy-
sis of 32 patients undergoing PSMA RLT and follow-up dual tracer staging with PSMA and FDG
PET/CT, FDG+/PSMA− lesions occurred in a limited number of patients. However, the presence of
FDG+/PSMA− lesions appears not to have a significant impact on the OS, but further studies are
needed to establish the clinical relevance of such lesions.
Abstract: Introduction: Positron emission tomography/computer tomography (PET/CT) targeting
the prostate-specific membrane antigen (PSMA) is crucial for the assessment of adequate PSMA
expression in patients with metastatic castration-resistant prostate cancer (mCRPC) prior to PSMA
radioligand therapy (PSMA RLT). Moreover, initial dual tracer staging using combined PSMA
and [18F]fluorodeoxyglucose (FDG) PET/CT provides relevant information, since discordant FDG-
positive but PSMA-negative (FDG+/PSMA−) lesions constitute a negative prognostic marker of
overall survival (OS) after PSMA RLT. However, little is known about the prognostic implications
of dual tracer imaging for restaging at follow-up. The aim of this analysis was to investigate the
prognostic implications of new FDG+/PSMA− lesions during or after PSMA RLT. Methods: This
bicentric analysis included 32 patients with mCRPC who underwent both FDG and PSMA PET/CT
imaging after two or four cycles of PSMA RLT. Patients with FDG+/PSMA− lesions prior to PSMA
RLT were not considered. The presence of FDG+/PSMA− lesions was assessed with follow-up
dual tracer imaging of patients after two or four cycles of PSMA RLT. Patients with at least one
new FDG+/PSMA− lesion were compared to patients without any FDG+/PSMA− lesions at the
respective time points. A log-rank analysis was used to assess the difference in OS between subgroups.
Results: After two cycles of PSMA RLT, four of 32 patients (13%) had FDG+/PSMA− metastases. No
significant difference in OS was observed (p = 0.807), as compared to patients without FDG+/PSMA−
lesions. Follow-up dual tracer imaging after the 4th cycle of PSMA RLT was available in 18 patients.
Of these, four patients presented with FDG+/PSMA− findings (n = 2 already after two cycles). After
the fourth cycle of PSMA RLT, no significant difference in OS was observed between patients with
and without FDG+/PSMA− lesions (p = 0.442). Conclusion: This study shows that FDG+/PSMA−
lesions develop in a limited number of patients undergoing PSMA RLT. Further studies are needed
to establish the clinical relevance of such lesions.
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1. Introduction
In the last decade, several strategies of drug treatment have successfully prolonged
survival in patients with metastatic castration-resistant prostate cancer (mCRPC), espe-
cially next-generation androgen receptor signaling inhibitors such as abiraterone and
enzalutamide [1,2], or chemotherapy with docetaxel and cabazitaxel [3–5]. Furthermore,
promising results for prostate-specific membrane antigen (PSMA-)-directed radioligand
therapy (RLT) with 177Lu-labelled PSMA-ligands in advanced disease stages have been
demonstrated [6–8]. The most important selection criterion for PSMA RLT is sufficient
expression of PSMA in tumor manifestation sites, as assessed by PSMA positron emission
tomography/computer tomography (PSMA PET/CT) [9]. However, patients scheduled
for PSMA-directed RLT are often heterogeneous both in terms of prior treatment as well
as tumor biology. Therefore, additional [18F]fluorodeoxyglucose (FDG) PET/CT stag-
ing becomes increasingly important, as it appears to be useful for the detection of more
aggressive disease [10,11] and may help in predicting and optimizing response rates to
RLT [12,13]. The LuPSMA Trial, which showed encouraging results for patients receiving
RLT [14,15] excluded patients in the case of discordant FDG-positive but PSMA-negative
(FDG+/PSMA−) lesions. These subjects showed a very poor overall survival (OS) under
standard of care [16]. Regarding patients with FDG+/PSMA− lesions on initial dual
tracer imaging, our group recently showed a reduced OS compared to patients without
FDG+/PSMA− lesions undergoing RLT [17]. Furthermore, as tumor PSMA expression may
decrease or be lost during several lines of treatment, additional FDG PET/CT scanning may
play an important role in the detection of such lesions over the course of therapy [14,18].
Up to now, dual tracer imaging has been mainly used for risk stratification at baseline
staging prior to PSMA RLT. The aim of this bi-centric retrospective study was to evaluate
the prognostic implications of newly developed FDG+/PSMA− lesions on dual tracer
follow-up imaging in patients undergoing PSMA-directed RLT. Therefore, FDG and PSMA
PET/CT scans of patients after two or four cycles of PSMA-directed RLT were analyzed,
and the results correlated to OS.
2. Materials and Methods
2.1. Patient Cohort
All patients who started their treatment with PSMA-directed RLT for mCRPC during
the period between August 2018 and January 2020, and who underwent PSMA and FDG
PET/CT before therapy initiation, were screened for eligibility at both participating sites
(University Hospital Würzburg, Wuerzburg, Germany. University Hospital Freiburg,
Freiburg, Germany). PSMA ligand PET/CT was performed to assess eligibility for PSMA-
directed RLT. In the case of adequate PSMA expression, the patients routinely underwent
a subsequent FDG PET/CT scan to assess the presence of PSMA-negative metastases.
Patients were included only if staging with both tracers was available after the 2nd therapy
cycle. An additional follow-up dual tracer staging after the 4th cycle was optional. Patients
with known FDG+/PSMA− lesions already on initial dual tracer staging before PSMA-
directed RLT were excluded from the current analysis to prevent the bias of the known
prognostic impact of initial FDG+/PSMA− lesions. An analysis of the initial staging
using PSMA and FDG PET/CT before PSMA-directed RLT has been previously published
for most of the patients [17]. Further exclusion criteria were missing survival data, an
intraindividual switch of PSMA ligands (i.e., from [68Ga]Ga-PSMA-11 to [18F]PSMA-1007)
during the course of therapy, and a time interval of ≥ 3 months between PET/CT and
application of the therapy. The median time of follow-up of surviving patients after two
cycles of PSMA RLT was 15 (95% confidence interval (CI) 12.8–17.2) months. The study
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was approved by the local ethics committees (University Hospital of Freiburg: protocol
No. 251/17; University Hospital of Wuerzburg: protocol No. 2019081501).
2.2. Imaging and Treatment Protocol
Imaging and treatment protocols have already been described elsewhere [17]. In
brief, whole-body PET scans were acquired using a PET/CT scanner with either full-dose
contrast-enhanced diagnostic CT (PSMA) or low-dose CT (FDG) for attenuation correction
and anatomical co-registration. Both PET/CT studies were performed on two separate days.
Standardized institutional protocols for RLT work-up were applied. In-house labeling was
carried out for [177Lu]-labelled PSMA ligands [177Lu]Lu-PSMA I&T (Wuerzburg, Germany),
and [177Lu]Lu-PSMA 617 (Freiburg, Germany). The standard PSMA RLT protocol consisted
of infusion of 6.0 GBq of the radioligand every 6–8 weeks with up to a maximum of 4 cycles
depending on response to treatment.
2.3. Image Analysis
PET/CT images were retrospectively analyzed using commercial software packages
(Wuerzburg: Syngo.via; VB30A, Siemens Healthcare, Erlangen, Germany; Freiburg: IMPAX
EE; Agfa Health Care, Bonn, Germany), as already described elsewhere [17]. All lesions
with non-physiological higher uptake of the PSMA ligand or FDG than the physiological
background were rated as PSMA- or FDG-positive, respectively. Images were visually
evaluated independently on each participating site by two nuclear medicine physicians (PH
and KM) using two categories: presence of one or more discordant lesions (FDG-positive
but PSMA-negative) or absence of FDG+/PSMA− lesions. In addition, the location and
the number of the FDG+/PSMA− lesions were noted. In case of visceral FDG+/PSMA−
metastases, the visibility on the CT was noted. The extent of metastases on PSMA PET/CT
was classified following the PROMISE Classification [19] with modifications: low tumor
burden (≤3 metastases), intermediate tumor burden (>3 but <10 metastases), high tumor
burden (≥10 metastases), and diffuse bone marrow involvement.
2.4. Statistical Analysis
Statistical analyses were performed using SPSS software version 27.0 (IBM,
Armonk, NY, USA). Descriptive data are presented as mean ± standard deviation and
range in parentheses. Survival data was analyzed by Kaplan–Meier curves and log-rank
comparison. OS was calculated starting with the date of the PSMA PET/CT after PSMA
RLT (i.e., after two or four cycles) and is presented as the median and 95% confidence inter-
val (CI) in square brackets. A p-value less than 0.05 was considered statistically significant.
3. Results
3.1. Patients’ Characteristics
A total of 59 patients (Wuerzburg: n = 31; Freiburg: n = 28) who underwent dual
tracer PET/CT prior to scheduled PSMA-directed RLT were screened for eligibility and
32 patients (Wuerzburg: n = 15; Freiburg: n = 17) were finally included into this analysis.
For 18 of these patients (Wuerzburg: n = 10; Freiburg: n = 8) dual tracer staging was also
available after the fourth treatment cycle. Figure 1 shows the inclusion process. Detailed
characteristics of all included patients are given in Table 1.
On initial PSMA PET/CT, a low tumor burden was found in one patient (3%). In
seven patients, an intermediate tumor burden was recorded (22%). The majority (n = 21;
66%) of patients showed a high tumor burden. Three patients presented with diffuse bone
marrow involvement (9%). In total, 107 cycles of RLT were administered with a mean
activity of 5.9± 0.6 (2.1–6.4) GBq per cycle.
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Figure 1. Flow diagram of patients included in this analysis undergoing PSMA radioligand ther-
apy (RLT) and dual tracer PET/CT. 
Table 1. Patients’ characteristics. 
 
After 2 Cycles of PSMA RLT 
(n = 32) 
After 4 Cycles of PSMA RLT 
(n = 18) 
Mean ± SD (Range) Mean ± SD (Range) 
Age (years) 72.6 ± 8.9 (46–90) 75.3 ± 9.8 (46–85) 
Time since diagnosis of prostate cancer (years) 8.1 ± 6.6 (2–26) 10.1 ± 7.8 (2–26) 
Gleason score at diagnosis (7–10) * (7–9) ** 
ECOG before PSMA RLT (0–2) (0–2) 
PSA before PSMA RLT [ng/mL] 389 ± 709 (5–2650) 384 ± 670 (5–2650) 
Sites of disease before PSMA RLT n % n % 
Prostate/local 13 41 7 39 
Lymph node 17 53 9 50 
Bone 30 94 18 100 
Liver 3 9 1 6 
Lung 4 13 3 17 
Other 3 9 2 11 
Previous treatment n % n % 
Prostatectomy 17 53 11 61 
Radiotherapy to prostate/prostate bed 15 47 9 50 
ADT 32 100 18 100 
Abiraterone 25 78 12 67 
Enzalutamide 19 59 13 72 
Docetaxel 21 66 11 61 
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Table 1. Cont.
After 2 Cycles of PSMA RLT
(n = 32)
After 4 Cycles of PSMA RLT
(n = 18)
Mean ± SD (Range) Mean ± SD (Range)
Enzalutamide 19 59 13 72
Docetaxel 21 66 11 61
Cabazitaxel 7 22 4 22
Other 6 19 3 11
ECOG: performance status according to Eastern Cooperative Oncology Group; PSA: prostate specific antigen, ADT: androgen deprivation
therapy, PSMA RLT: prostate-specific membrane antigen-targeted radioligand therapy; other therapies: selective internal radiation
therapy, PSMA RLT, Carboplation, Estramustin, Prostvac, Gemcitabine, Olaparib; other sites of disease: adrenal gland, testis, peritoneal
carcinomatosis; * unknown in five patients; ** unknown in four patients.
3.2. Dual Tracer Staging after Two Cycles of PSMA RLT
After two cycles of PSMA-directed RLT, four of 32 patients (13%) showed FDG+/PSMA−
metastases in the following organ systems: lymph nodes (n = 1), bones (n = 1), liver (n = 1),
as well as liver and peritoneum (n = 1). The median number of FDG+/PSMA− findings
was 2 (1–4). The liver metastases were only seen on FDG PET, not on the CT scan (one of
these patients was examined with an unenhanced CT because of hyperthyroidism; Table 2).
Table 2. Findings of the patients with discordant lesions after two and four cycles of PSMA RLT.
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the current analysis) showed a significantly shorter OS after two cycles than the 32 patients included 
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radioligandtherapy with new FDG+/PSMA− liver metastases (black arrows); (b) fixed inverse gray-scale are displayed
with SUV window setting from 0 to 20 ([18F]PSMA-1007 PET) and 0 to 5 (FDG PET), respectively.
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The following organ systems were affected: bones (n = 1), lymph nodes (n = 1), liver
(n = 1), as well as liver and peritoneum (n = 1). The median number of FDG+/PSMA−
findings was five (1–9). In one patient, the hepatic lesions were only found on the FDG PET
scan, but not on the unenhanced CT scan. The peritoneal carcinomatosis in the same patient,
as well as the liver metastases in the other patient, were visible on both FDG PET and CT
(Table 2). The OS of all patients (n = 18) calculated after four cycles of PSMA-directed RLT
was 11 (95% CI 8.8–13.2) months. No significant difference for OS was found between the
four patients with FDG+/PSMA− findings on dual tracer PET/CT after the fourth cycle
(median OS not reached at the end of the follow-up period) and the 14 patients without
FDG+/PSMA− lesions (median OS 10 (95% CI 7.2–12.8) months; p = 0.442, Figure 4).
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(95% CI 7.2–12.8) months; p = 0.442).
4. Discussion
While the prognostic relevance of FDG+/PSMA− PET-findings prior to PSMA RLT
has recently been demonstrated [17], the present analysis f cused on the development
FDG+/PSMA− findings in th course of PSMA-directed RLT and assessed the potential
prog ostic value f repeated dual tracer imaging.
Rosar et al. studied 52 patients with dual tracer PET/CT over the course of PSMA-
directed RLT, but detailed information about the time points or initial imaging was not
given. FDG+/PSMA− findings were found in 28 of 52 patients (54%) [20], which is clearly
higher than in our study cohort with 4 of 32 patients (13%) after the second cycle or 4 of 18
patients (22%) after the fourth cycle of PSMA RLT. This could be due to the fact that we
excluded patients with FDG+/PSMA− lesions on initial dual tracer staging before PSMA
RLT in our analysis. The appearance of FDG+/PSMA− lesions under PSMA RLT might
reflect genomic dedifferentiation as a possible resistance mechanism to PSMA-directed
therapy. Surprisingly, the presence of FDG+/PSMA− findings after the second and fourth
cycle of PSMA RLT turned out not to be a prognostic marker in our study cohort. This might
suggest that the assessment of an additional FDG PET/CT scan may be only reasonable
for initial staging before PSMA RLT [17]. However, these results are limited due to the
small number of patients in our patient cohort and need further investigations. Results
of Emmett et al. [21] indicate that other parameters (such as the maximum standardized
uptake value) and volume or site of disease on FDG PET are not prognostic markers for
serological response, neither on initial staging nor after completion of therapy.
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However, in terms of diagnostic accuracy, FDG PET might help to detect liver metas-
tases, especially in [18F]PSMA-1007 PET scans, which can be false negative due to the high
physiological hepatic tracer uptake [22]. Although previous analyses have shown that the
presence of visceral metastases, especially liver metastases, results in poor survival for
patients undergoing RLT [17,23,24], disease control of patients with PSMA-positive liver
metastases is still possible in approximately half of cases (46%) [25]. Therefore, the detection
of PSMA-negative liver metastases is very important regarding possible discontinuation of
PSMA-directed RLT. We observed one patient with liver metastases found only by FDG
PET on follow-up imaging, but not with the contrast-enhanced CT scan. However, this
patient was examined with [18F]PSMA-1007 PET/CT, and the FDG+/PSMA− assessment
might be due to the hepatobiliary excretion of [18F]PSMA-1007 [22]. Thus, if the possible
detection of PSMA-negative liver metastases justifies the routine use of FDG PET/CT
remains questionable.
Apart from that, in some cases, it might be useful to perform additional FDG PET/CT,
if neuroendocrine dedifferentiation is suspected (e.g., loss of tracer-uptake on PSMA
PET/CT, increase of neuron-specific enolase [20], PSA negative follow-up) for choosing the
right therapy management, but we cannot provide data on this issue. FDG PET/CT could
then also be used for therapy monitoring. Apart from FDG PET, nomograms of PSMA
PET scans might be another possible tool for an improved patient selection for staging and
restaging of patients with (metastasized) prostate cancer [26,27].
Patients showed a median survival of 14 months after the second cycle and 11 months
after the fourth cycle. This is apparently longer when compared to the OS of 11 months
for all patients treated with RLT after beginning of the first cycle, which was published
recently [17]. This is probably due to a selection bias of our study, which analyzes only
those patients without initial FDG+/PSMA− lesions and known reduced response to
therapy. Furthermore, our analysis does not include the data of 16 patients who were
treated with one or two cycles of PSMA RLT, but who did not undergo PET/CT restaging
due to clinical disease progression with discontinuation of PSMA RLT. Therefore, the
percentage of patients with FDG+/PSMA− metastases can be underestimated.
Additional limitations of this retrospective study include the small sample size, espe-
cially for follow-up dual PET/CT after the fourth cycle of PSMA RLT, which included only
18 patients. However, this study constitutes the first systematic analysis of FDG+/PSMA−
lesions in sequential dual tracer PET/CT in patients undergoing PSMA RLT. No histopatho-
logical proof of FDG−/PSMA+ metastases was undertaken and a false positive rating (i.e.,
in case of an inflammation) cannot be completely ruled out, although it seems unlikely as
all scans were also evaluated with regard to their CT scan. PET/CT examinations using
both [68Ga]- and [18F]-labelled PSMA ligands were included, as both hospitals changed the
radiolabeling procedure during the study period. Despite this fact, the included follow-up
PSMA PET scans of a given patient were strictly performed with the same PSMA ligand
only. Moreover, in order to deal with potential differences of the PSMA ligands, a visual
categorization system as described before was used [17]. Within this framework, the im-
pact of different PET/CT scanners used at the two institutions for the visual assessment is
probably negligible.
5. Conclusions
This study shows that FDG+/PSMA− lesions develop in a limited number of patients
undergoing PSMA RLT. Further studies are needed to establish the clinical relevance of
such lesions.
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